What is Zacks Research’s Forecast for PBH FY2026 Earnings?

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Stock analysts at Zacks Research lifted their FY2026 earnings per share estimates for Prestige Consumer Healthcare in a research note issued to investors on Monday, July 14th. Zacks Research analyst R. Department now expects that the company will earn $4.74 per share for the year, up from their prior forecast of $4.73. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share.

A number of other analysts also recently commented on PBH. Royal Bank Of Canada upgraded Prestige Consumer Healthcare to a “hold” rating in a research note on Thursday, May 8th. Wall Street Zen raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $93.33.

Prestige Consumer Healthcare Stock Up 0.8%

Shares of PBH opened at $75.70 on Thursday. Prestige Consumer Healthcare has a 52 week low of $64.94 and a 52 week high of $90.04. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $3.74 billion, a price-to-earnings ratio of 17.65, a PEG ratio of 2.25 and a beta of 0.43. The stock’s 50-day moving average price is $82.92 and its 200-day moving average price is $82.26.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The firm had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. During the same quarter in the prior year, the business earned $1.02 earnings per share. The company’s revenue was up 7.0% compared to the same quarter last year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Large investors have recently bought and sold shares of the business. UMB Bank n.a. raised its holdings in Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after purchasing an additional 144 shares during the period. Maseco LLP acquired a new position in shares of Prestige Consumer Healthcare during the second quarter valued at approximately $27,000. CIBC Private Wealth Group LLC raised its holdings in shares of Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after acquiring an additional 152 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of Prestige Consumer Healthcare during the first quarter valued at approximately $38,000. Finally, Headlands Technologies LLC acquired a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $40,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.